Gilder Gagnon Howe & Co’s Erasca ERAS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ERAS Stock Details ERAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-56,597	Closed	-$916K	–	283
2026 Q1	$916K	Buy	+56,597	New	+$669K	0.01%	221

Other funds holding ERAS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Gilder Gagnon Howe & Co's ERAS Position: Q2 2026 in Review

Gilder Gagnon Howe & Co sold out of Erasca (ERAS) in Q2 2026, closing a stake of 56,597 shares — an estimated $916K sold.

Gilder Gagnon Howe & Co first reported a position in ERAS in Q1 2026 and held it in 1 quarter. The position peaked at $916K in Q1 2026. 256 funds tracked by Wall St. Rank hold ERAS as of Q2 2026.

Gilder Gagnon Howe & Co reported no remaining Erasca position as of Q2 2026 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 56,597 Erasca shares in Q2 2026, an estimated $916K.
Gilder Gagnon Howe & Co first reported a position in Erasca in Q1 2026 and held it in 1 quarter.
Gilder Gagnon Howe & Co's Erasca position peaked at $916K in Q1 2026.
256 funds tracked by Wall St. Rank held Erasca as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.